SCOTTSDALE, AZ -- (Marketwire) -- 05/14/09 -- ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced it has entered into a sponsored research agreement with Ted M. Ross, Ph.D., an assistant professor at the University of Pittsburgh's Center for Vaccine Research. Dr. Ross, a respected leader in his field, will explore the use of ImmuneRegen's lead influenza therapeutic product, Viprovex®, as an adjuvant to novel influenza vaccines.
Dr. Ross is renowned for his research and development of effective vaccines for influenza, HIV-1, and emerging infectious diseases. He has extensive experience in evaluating immune response characteristics in preclinical models for various influenza and HIV vaccines, including virus-like particle (VLP)-based vaccines, and he has established animal models to assess both cellular and humoral immune responses to antigens. His most recent publications have evaluated the efficacy of an H5N1 VLP-based vaccine.
Viprovex, a derivative of Homspera, already is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant.
In studies of influenza-infected animals performed at other research facilities, ImmuneRegen's Viprovex® has consistently demonstrated efficacy in reducing symptoms related to seasonal (e.g. H1N1 and H3N2) influenza and highly-pathogenic (e.g. H5N1) influenza strains. The current pandemic "Swine Flu" (H1N1) has many attributes of typical seasonal influenza strains.
Previous studies, also performed at other research facilities, revealed Viprovex used as a vaccine adjuvant increased concentrations in blood of antibodies against both the virus used for vaccination as well as cross-reactive antibodies against different influenza strains, a desired effect as the virus components in influenza vaccines often do not exactly match the influenza viruses causing illness.
About ImmuneRegen BioSciences Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona-based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute, Virion Systems, University of Rochester and University of Pittsburgh. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-KSB for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.